• Corpus ID: 45874136

A fixed-dose combination ibuprofen and famotidine (Duexis).

@article{2011AFC,
  title={A fixed-dose combination ibuprofen and famotidine (Duexis).},
  author={},
  journal={The Medical letter on drugs and therapeutics},
  year={2011},
  volume={53 1376},
  pages={
          85-6
        }
}

• Published 2011
• Medicine
• The Medical letter on drugs and therapeutics

The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers. Vimovo, a combination of the NSAID naproxen and the proton pump inhibitor (PPI) esomeprazole, is also approved by the FDA for prevention of NSAID-associated gastric ulcers.